查找临床试验
已按「地中海贫血」检索，对应国际通用词 thalassemia
共找到 37 项正在招募的试验（在欧美日韩等发达国家设有中心）
数据更新于 00:19，每 5 分钟自动同步Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
United States
年龄 18 Years – 70 Years
National Institute of Allergy and Infectious Diseases (NIAID)
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
United States
年龄 2 Months – 55 Years
Paul Szabolcs
Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia
Canada
年龄 1 Year – 18 Years
The Hospital for Sick Children
European Rare Blood Disorders Platform (ENROL)
Spain
年龄 不限 – 100 Years
Hospital Universitari Vall d'Hebron Research Institute
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
United States
年龄 6 Months – 21 Years
New York Medical College
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
United States、Australia、Belgium、Bulgaria、Canada 等 12 国
年龄 18 Years – 不限
Celgene
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
United States、China、Germany、Greece、India 等 9 国
年龄 6 Years – 17 Years
Celgene
A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia
South Korea
年龄 19 Years – 不限
Bristol-Myers Squibb
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
United States
年龄 13 Years – 40 Years
Daniel Bauer
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
United States、Canada、Egypt、France、Germany 等 12 国
年龄 2 Years – 不限
Novo Nordisk A/S
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
United States
年龄 1 Day – 30 Years
Mitchell Cairo
International Registry of Patients With Alpha Thalassemia
United States
年龄 不限 – 不限
University of California, San Francisco